EpiBiologics closed a $107 million Series B, backed by investors including GV and Johnson & Johnson’s venture arm, to advance its surface‑targeted protein degradation platform (EpiTACs) and lead candidate EPI‑326 into first‑in‑human studies in 1H 2026. The Bay Area startup said EPI‑326 selectively degrades oncogenic EGFR on tumors and has a favorable preclinical safety profile that supports single‑agent and combination strategies. The funding round elevates interest in targeted protein degradation beyond small‑molecule PROTACs, applying degrader concepts to extracellular targets. Strategic investors and partnerships with large pharmas underscore commercial and translational confidence for the modality. Near term investors will monitor IND filings, the chosen first‑in‑human indication, and early combination cohorts.